Publications by authors named "Cedric Revil"

Claim this Profile
P
Population-level impact of adjuvant trastuzumab emtansine on the incidence of metastatic breast cancer: an epidemiological prediction model of women with HER2-positive early breast cancer and residual disease following neoadjuvant therapy.
Mellissa Williamson, David J Press, Svenn Alexander Hansen, Akanksha Tomar, Gurleen Singh Jhuti, Cedric Revil

Breast Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply: RE: Reyes A, Révil C, Niggli M, et al. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Curr Med Res Opin. 2019;35(12):2079-2087.
Adriana Reyes, Cédric Révil, Markus Niggli, Sammy Chebon, Simone Schlagmüller

Curr Med Res Opin· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial.
Adriana Reyes, Cédric Révil, Markus Niggli, Sammy Chebon, Simone Schlagmüller

Curr Med Res Opin· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio.
Martha Nowosielski, Benjamin M Ellingson, Olivier L Chinot, Josep Garcia, Cedric Revil

Neuro Oncol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns and outcomes for patients with locally advanced basal cell carcinoma before availability of Hedgehog pathway inhibitors: a retrospective chart review.
John T Lear, Nicole Basset-Seguin, Martin Kaatz, Thomas Jouary, Laurent Mortier, Cedric Revil

Eur J Dermatol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
Wolfgang Wick, Olivier L Chinot, Martin Bendszus, Warren Mason, Roger Henriksson, Cedric Revil

Neuro Oncol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.
Olivier L Chinot, Ryo Nishikawa, Warren Mason, Roger Henriksson, Frank Saran, Cedric Revil

Neuro Oncol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy?
Alba A Brandes, Warren Mason, Josef Pichler, Anna K Nowak, Miguel Gil, Cedric Revil

Future Oncol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and cost effectiveness of bevacizumab + FOLFIRI combination versus FOLFIRI alone as first-line treatment of metastatic colorectal cancer in South Korea.
Eui-Kyung Lee, Cedric Revil, Charles A Ngoh, Johanna Lister, Jeong-Mi Kwon

Clin Ther· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Bella Kaufman, John R Mackey, Michael R Clemens, Poonamalle P Bapsy, Ashok Vaid

J Clin Oncol· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis